Overview

The Impact of Metformin on the Outcome of Gouty Arthritis in a Cohort of Egyptian Gouty Patients.

Status:
Not yet recruiting

Trial end date:
2023-04-01

Target enrollment:
0

Participant gender:
All

Summary

Objective: To study the impact of metformin on the outcome of gouty arthritis in a cohort of Egyptian gouty patients, and to evaluate its effect on local joint inflammation, inflammatory cytokines (IL-1β and IL-6), and life quality. Methods: A prospective randomized, single-blinded parallel randomized control study included 250 patients with active inflammatory gouty arthritis were randomized to receive metformin (1000mg/day) or placebo in addition to the traditional lines of treatment of gout. The clinical and laboratory data of the patients will be analyze at baseline, then after 6, and 12 months, with the assessment of gout disease activity, in addition, serum IL-1β and IL-6, the number of attacks per year, treatment satisfaction, quality of life, and disability index were evaluated at the 12th month from starting metformin and placebo therapy.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Menoufia University

Treatments:

Metformin

Criteria

Inclusion Criteria:

- gouty patients who fulfilled the American College of Rheumatology clinical criteria.

- gouty patients with active inflammatory arthritis.

Exclusion Criteria:

- Patients with any type of inflammatory arthritis.

- Patients with systemic disease as diabetes, hypertension,

- Patients with hyperlipidemia, coronary artery disease,

- Patients with renal or hepatic insults,

- pregnant and lactating females